Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights
— Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021
Source: leaderpost.com